What we do

isoSolutions Marketing & Management Inc. offers a wide range of products for nuclear medicine applications, from a variety of reliable suppliers, providing a one-stop shopping service as well as technical support.

David

David T. Drummond Managing Director

People matter the most. Every organization should aim to leave people better off. In the health sector that starts with the patient but must also include our suppliers, customers, employees, partners — indeed, everyone whose life is touched by our company.

85

Companies connected
through isoSolutions

350

Orders delivered
worldwide in 2017

94%

Orders delivered
on time in 2017

News

19th China Cardiovascular and Nuclear Medicine Annual meeting

Hans Peng ⎜ Jul 11, 2018

isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine (http://www.csnm.com.cn/) in Sichuan, China.

The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. The meeting will focus on the progress of diagnosis and treatment of nuclear medicine in China, the clinical trial of imaging medicine and nuclear medicine. Also its applications and advances in related fields such as cancer, cardiovascular, neurology, etc.

The conference will also discuss the reports and hot topics PET/CT and molecular imaging clinical applications and radionuclide treatment; the conference has invited experts from clinical disciplines and imaging disciplines. they will conduct a wide range of communication and discussion on how to improve the diagnostic and therapeutic level of imaging medicine and nuclear medicine, promote the clinical work of imaging medicine and nuclear medicine, promote and popularize the clinical application of imaging medicine and nuclear medicine.

We sincerely hope that relevant medical and scientific personnel from all over the country will participate in the conference. In order to strengthen the communication between imaging and clinical subjects, we will promote the development of imaging medicine and nuclear medicine in China.

We especially look forward to experts in internal medicine, surgery, radiology, ultrasound and nuclear medicine. For more info: http://www.csnm.com.cn/special/65

keep reading

SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer

David T. Drummond ⎜ Jun 29, 2018

PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), researchers reported on a phase II prospective trial. Using gallium-68 (68Ga)-PSMA11 positron emission tomography (PET) imaging, men who had exhausted conventional therapies were screened. Those with high PSMA-expression proceeded to 177Lu-PSMA617 (LuPSMA) therapy and experienced high response rates, which is clearly demonstrated in the PSMA PET imaging figure selected as the 2018 SNMMI Image of the Year.

Each year, SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to improve patient care by detecting disease, aiding diagnosis, improving clinical confidence and providing a means of selecting appropriate treatments. This year, the SNMMI Henry N. Wagner, Jr., Image of the Year was chosen from more than 2,200 abstracts submitted to the meeting and voted on by reviewers and the society leadership.
The 2018 Image of the Year goes to a team of researchers at the Peter MacCallum Cancer Centre in Melbourne, Australia. The image demonstrates exceptional responses in a series of patients who received LuPSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET. These patients experienced improved quality of life, including reduction of pain, and correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.
“This work reflects an appreciation for all the basic science and translation work that has been performed by many groups over a long period of time to develop prostate-specific membrane antigen (PSMA) theranostics as a paradigm-changing practice for improving patient outcomes,” explained Professor Michael Hofman of the Peter MacCallum Cancer in Melbourne, Australia. “These images tell a story about exceptional responses observed in patients who had progressed after standard therapies. They match striking improvements in patient quality of life. With further research, we look forward to seeing nuclear medicine evolve as a key specialty and standard-of-care in cancer management.” He added, “I would also like to extend thanks to ANSTO, Australia’s producer of no-carrier-added Lutetium-177, and Endocyte, which produces PSMA; they helped make this study possible.”

Umar Mahmood, MD, PhD, chair of the SNMMI Scientific Program Committee, noted, “The last decade has seen a blossoming of theranostics to treat tumors with molecularly-guided radiotherapy. The expansion of patients benefiting from this approach is remarkable, and it is wonderful to know that this effort is being led by nuclear medicine physicians and scientists.”
Mahmood stated, “Prostate cancer, which affects millions of men around the world, can be painful and deadly in the metastatic setting. This phase II prospective study by Michael Hofman and colleagues clearly shows the benefit to men with castrate-resistant prostate cancer treated with a beta emitter targeting PSMA when their tumors expressed PSMA. It is gratifying to see the benefit of the approach both rigorously and objectively demonstrated in this trial, in terms of improvement in disease burden and improvement in the pain severity the men suffered.”

Abstract 531: “High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial,” Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

keep reading

Calendar

Jul 12 to 15

Chinese Society of Nuclear Medicine Annual Meeting 2018

The Chinese Society of Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from 2018–07–12 to 2018–07–15. We hope to see you there and we can arrange a time and place to meet if you wish.

Jun 23 to 26

Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2018

Pennsylvania Convention Center, Headquarter Hotel: Philadelphia Marriott. isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Mar 23 to 24

Canadian Nuclear Medicine Scientific Meeting 2018

isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Vancouver, BC from 2018–03–23 to 2018–03–24.